TAF based regimen (TBR) — Competitive Intelligence Brief

TAF based regimen (TBR) (TAF based regimen (TBR)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor (NtRTI). Area: Infectious Disease / Virology.

phase 3 Nucleotide reverse transcriptase inhibitor (NtRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

TAF based regimen (TBR) (TAF based regimen (TBR)) — ViiV Healthcare. TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAF based regimen (TBR) TARGET	TAF based regimen (TBR)	ViiV Healthcare	phase 3	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Antiretroviral therapy plus Interleukin-2	Antiretroviral therapy plus Interleukin-2	Juan A. Arnaiz	marketed	Combination immunotherapy and antiviral	HIV reverse transcriptase, protease, integrase (ART component); IL-2 receptor (IL-2 component)
Efavirenz or Nevirapine	Efavirenz or Nevirapine	University of Aarhus	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Arm A: ABC+3TC+NNRTI	Arm A: ABC+3TC+NNRTI	Medical Research Council	marketed	Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor)	HIV reverse transcriptase
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor (NtRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
2. Humanity and Health Research Centre · 1 drug in this class
3. New Discovery LLC · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class